Breaking News
Investing Pro 0
💎 Reveal Undervalued Stocks Hiding in Any Market Get Started
Close

Amgen Inc (AMGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9,783.500 +96.500    +1.00%
15:56:00 - Closed. Currency in ARS ( Disclaimer )
  • Volume: 845
  • Bid/Ask: 9,783.500 / 9,830.000
  • Day's Range: 9,654.000 - 9,812.500
Type:  Equity
Market:  Argentina
ISIN:  ARDEUT110665 
Amgen 9,783.500 +96.500 +1.00%

Amgen Company Profile

 
Get an in-depth profile of Amgen Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

24200

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Contact Information

Address One Amgen Center Drive
Thousand Oaks, 91320-1799
United States
Phone 805 447 1000
Fax 805 447 1010

Top Executives

Name Age Since Title
Robert A. Bradway 58 2007 Chairman, CEO & President
R. Sanders Williams 74 2014 Independent Director
Maria T. Abreu - 2022 Member of Scientific Advisory Board of Inflammation
Thaddeus Stappenbeck - 2022 Member of Scientific Advisory Board of Inflammation
Emma Guttman-Yassky - 2022 Member of Scientific Advisory Board of Inflammation
Meilan Han - 2022 Member of Scientific Advisory Board of Inflammation
Ronald D. Sugar 74 2010 Independent Director
Greg C. Garland 66 2013 Independent Director
Charles M. Holley 66 2017 Independent Director
Robert A. Eckert 69 2012 Lead Independent Director
Tyler E. Jacks 62 2012 Independent Director
Ellen J. Kullman 67 2016 Independent Director
S. Omar Ishrak 67 2021 Independent Director
Alexander Marson - 2022 Member of Scientific Advisory Board of Inflammation
Arlene Sharpe - 2022 Member of Scientific Advisory Board of Inflammation
Dean Sheppard - 2022 Member of Scientific Advisory Board of Inflammation
Brian J. Druker 67 2018 Independent Director
Amy E. Miles 56 2020 Independent Director
Wanda M. Austin 69 2017 Independent Director
Alexander Rudensky - 2022 Member of Scientific Advisory Board of Inflammation
Michael V. Drake - 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AMGN Comments

Write your thoughts about Amgen
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email